Trade Mark Journal No.2026/013 27 March 2026
WO0000001892409 (42,44)
Office of origin: United States of America
Date of International Registration:22 October 2025
Date of designation in the UK:
22 October 2025

International priority date claimed: 24 April 2025
(United States of America)
(99153728)
- Class 42
- Medical and scientific research in the field of oncology; providing medical and scientific research information in the field of oncology; medical and scientific research, namely, whole genome and whole transcriptome sequencing assays for biomarker detection and analysis in patients with leukemia, lymphoma, myeloma, or other hematologic malignancies.
- Class 44
- Medical testing for diagnostic, prognostic, or treatment purposes; medical testing, namely, whole genome and whole transcriptome sequencing assays for biomarker detection in patients with leukemia, lymphoma, myeloma, or other hematologic malignancies.
Caris MPI, Inc.
Representative: Anne Fleeson Womble Bond Dickinson (US) LLP, One West Fourth Street, Winston-Salem NC 27101, UNITED STATES OF AMERICA